An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Dalzanemdor (Primary)
- Indications Dementia; Mild cognitive impairment
- Focus Adverse reactions
- Acronyms LUMINARY
- Sponsors Sage Therapeutics
- 04 Aug 2022 Results reporting safety/tolerability of SAGE-718 and its effects on cognitive symptoms in patients with AD presented at the Alzheimer's Association International Conference 2022
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 01 Apr 2022 According to a SAGE Therapeutics media release, data from this trial will be presented during the Emerging Science Session at the 74th Annual Meeting of the American Academy of Neurology (AAN) 2022.